Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
2 "Corticobasal degeneration"
Filter
Filter
Article category
Keywords
Publication year
Authors
Case Reports
Article image
Suppression of Myoclonus in Corticobasal Degeneration by Levetiracetam
Jae Wook Cho, Jae Hyeok Lee
J Mov Disord. 2014;7(1):28-30.   Published online April 30, 2014
DOI: https://doi.org/10.14802/jmd.14007
  • 11,175 View
  • 105 Download
  • 13 Web of Science
  • 11 Crossref
AbstractAbstract PDF
Myoclonus in corticobasal degeneration (CBD) has often been associated with severe and difficult to treat disabilities. Levetiracetam is a new antiepileptic agent with antimyoclonic effects. Herein, we present a 72-year-old woman with clinically probable CBD and with spontaneous rhythmic myoclonus in the right foot, which was markedly ameliorated through treatment with levetiracetam. The effect of levetiracetam was associated with the decreased amplitude of enlarged cortical somatosensory evoked potentials. This result suggests that the antimyoclonic effect of levetiracetam might be mediated through the suppression of increased cortical excitability.

Citations

Citations to this article as recorded by  
  • Management Strategies for Atypical Parkinsonism
    Vasilios C. Constantinides, Nikolaos Giagkou, Maria-Evgenia Brinia, Christos Koros, Leonidas Stefanis, Maria Stamelou
    Current Treatment Options in Neurology.2024; 26(5): 169.     CrossRef
  • Chinese nutraceuticals and physical activity; their role in neurodegenerative tauopathies
    Abdullahi Alausa, Sunday Ogundepo, Barakat Olaleke, Rofiat Adeyemi, Mercy Olatinwo, Aminat Ismail
    Chinese Medicine.2021;[Epub]     CrossRef
  • Four-Repeat Tauopathies: Current Management and Future Treatments
    Lawren VandeVrede, Peter A. Ljubenkov, Julio C. Rojas, Ariane E. Welch, Adam L. Boxer
    Neurotherapeutics.2020; 17(4): 1563.     CrossRef
  • Physiology-Based Treatment of Myoclonus
    Ashley B. Pena, John N. Caviness
    Neurotherapeutics.2020; 17(4): 1665.     CrossRef
  • Pharmacological interventions in corticobasal degeneration: a review
    Leonardo Caixeta, Victor de Melo Caixeta, Yanley Lucio Nogueira, Tales Alexandre Aversi-Ferreira
    Dementia & Neuropsychologia.2020; 14(3): 243.     CrossRef
  • Available and future treatments for atypical parkinsonism. A systematic review
    Davide Vito Moretti
    CNS Neuroscience & Therapeutics.2019; 25(2): 159.     CrossRef
  • An Update on Myoclonus Management
    Christine M. Stahl, Steven J. Frucht
    Expert Review of Neurotherapeutics.2019; 19(4): 325.     CrossRef
  • Corticobasal degeneration: key emerging issues
    F. Ali, K. A. Josephs
    Journal of Neurology.2018; 265(2): 439.     CrossRef
  • Focal Predominant Forms of Posthypoxic Action Myoclonus
    Carmen Gasca‐Salas, Anthony E. Lang
    Movement Disorders Clinical Practice.2016; 3(4): 417.     CrossRef
  • Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options
    Ruth Lamb, Jonathan D. Rohrer, Andrew J. Lees, Huw R. Morris
    Current Treatment Options in Neurology.2016;[Epub]     CrossRef
  • An Update and Review of the Treatment of Myoclonus
    Kelly Mills, Zoltan Mari
    Current Neurology and Neuroscience Reports.2015;[Epub]     CrossRef
Neuroleptic Malignant Syndrome in a Patient with Corticobasal Degeneration
Myung Jun Lee, Chul Hyoung Lyoo, Myung Sik Lee
J Mov Disord. 2011;4(2):73-74.
DOI: https://doi.org/10.14802/jmd.11015
  • 10,861 View
  • 56 Download
  • 1 Crossref
AbstractAbstract PDF

Parkinson’s disease is a principal underlying disease of neuroleptic malignant syndrome (NMS) occurring in parkinsonian disorders, but NMS may occur in patients with progressive supranuclear palsy and multiple system atrophy. We report first patient with corticobasal degeneration (CBD) who developed NMS after abrupt reduction of antiparkinsonian medication and concurrent infection. It should be kept in mind that the prevention of infectious illness, which is common complication in parkinson-plus syndrome, is important, and dose reduction or withdrawal of anti-parkinsonian medications should be carefully performed even in the patients with CBD who are expected to be unresponsive to levodopa treatment.

Citations

Citations to this article as recorded by  
  • Diagnosis and Management of Progressive Corticobasal Syndrome
    Claire Delpirou Nouh, Kyan Younes
    Current Treatment Options in Neurology.2024; 26(7): 319.     CrossRef

JMD : Journal of Movement Disorders Twitter
Close layer
TOP